SWK Holdings Corp. is engaged in the business of financial and asset management in the field of pharmaceutical. The company offers capital and investments in life science companies, institutions and inventors. It engages in royalty purchases and financings, as well as commercialization of products. The firm operates through the following segments: Finance Receivables and Pharmaceutical Development. The Finance Receivables segment is a healthcare capital provider which offers customized financing solutions to a broad range of life science companies, institutions and inventors. It is primarily focused on monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. The Pharmaceutical Development segment strategy is to utilize the Peptelligence platform to create a wholly-owned portfolio of milestone and royalty income by out-licensing the technology. The company was founded in July 1996 and is headquartered in Dallas, TX.